| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2125332 | European Journal of Cancer | 2009 | 13 Pages |
Abstract
Our data indicate that down-regulation of BIM is epigenetically controlled by methylation in a percentage of CML patients and has an unfavourable prognostic impact, and that the combination of imatinib with a de-methylating agent may result in improved responses in patients with decreased expression of BIM.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Edurne San José-Eneriz, Xabier Agirre, Antonio Jiménez-Velasco, Lucia Cordeu, Vanesa MartÃn, Victor Arqueros, Leire Gárate, Vicente Fresquet, Francisco Cervantes, José A. MartÃnez-Climent, Anabel Heiniger, Antonio Torres, Felipe Prósper,